---
figid: PMC5962346__nihms923919f1
figtitle: Molecular targets for therapy in the HH pathway web of collaboration
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC5962346
filename: nihms923919f1.jpg
figlink: /pmc/articles/PMC5962346/figure/F1/
number: F1
caption: Molecular targets for therapy in the HH pathway web of collaboration. The
  HH pathway interacts with various other signaling networks that synergistically
  contribute to tumor development. PTCH is a 12-pass transmembrane receptor that generally
  represses SMO. HH binding to PTCH or inactivating PTCH mutations suppress this repressive
  response and allow for the translocation of SMO to the primary cilium to induce
  GLI transcription. The mTOR pathway helps release GLI from SUFU through S6K1 mediated
  GLI phosphorylation. The IGF/ PI3K/AKT and EGFR/MEK/ERK pathways modulate PKA-dependent
  phosphorylation of GLI. In the hippo pathway, MST1/2 kinases and SAV1 form a complex
  to phosphorylate and activate LATS1/2 and MOB1. In turn, LATS1/2 dephosphorylates
  YAP/TAZ, allowing the complex to translocate the nucleus and to interact with TEAD1-4
  to induce the expression of genes that promote tumor progression. The aggrandizing
  effect of these various pathways results in BCC development, progression, and tumor
  resistance. Inhibiting various players within this crosstalk may lead to effective
  and resistance-proof treatment modalities. SMO antagonists, crosstalk pathway inhibitors,
  GLI antagonists, HDAC inhibitors, bromodomain inhibitors, and verteporfin target
  these various pathways to curb tumor development
papertitle: Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling
  and beyond.
reftext: Anshika Bakshi, et al. Mol Carcinog. ;56(12):2543-2557.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9406329
figid_alias: PMC5962346__F1
figtype: Figure
redirect_from: /figures/PMC5962346__F1
ndex: 8bec2211-df05-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5962346__nihms923919f1.html
  '@type': Dataset
  description: Molecular targets for therapy in the HH pathway web of collaboration.
    The HH pathway interacts with various other signaling networks that synergistically
    contribute to tumor development. PTCH is a 12-pass transmembrane receptor that
    generally represses SMO. HH binding to PTCH or inactivating PTCH mutations suppress
    this repressive response and allow for the translocation of SMO to the primary
    cilium to induce GLI transcription. The mTOR pathway helps release GLI from SUFU
    through S6K1 mediated GLI phosphorylation. The IGF/ PI3K/AKT and EGFR/MEK/ERK
    pathways modulate PKA-dependent phosphorylation of GLI. In the hippo pathway,
    MST1/2 kinases and SAV1 form a complex to phosphorylate and activate LATS1/2 and
    MOB1. In turn, LATS1/2 dephosphorylates YAP/TAZ, allowing the complex to translocate
    the nucleus and to interact with TEAD1-4 to induce the expression of genes that
    promote tumor progression. The aggrandizing effect of these various pathways results
    in BCC development, progression, and tumor resistance. Inhibiting various players
    within this crosstalk may lead to effective and resistance-proof treatment modalities.
    SMO antagonists, crosstalk pathway inhibitors, GLI antagonists, HDAC inhibitors,
    bromodomain inhibitors, and verteporfin target these various pathways to curb
    tumor development
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - smo
  - sufu
  - igfn1.2
  - tnfrsfa
  - tnfb
  - egf
  - celsr1a
  - gli
  - mtor
  - rab1ab
  - mst1
  - cby1
  - lats1
  - cki
  - tafazzin
  - cat
  - hey1
  - ccnd1
  - gli1
  - hhip
  - ccn2a
  - ccn2b
  - ccn1
  - ccn1l2
  - ccne1
  - igf2bp1
  - SMO
  - SMOX
  - SUFU
  - IGF1
  - TNF
  - EGF
  - PTCH1
  - GLI1
  - SERPINB10
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - RRBP1
  - HES1
  - HES2
  - HES3
  - HES4
  - HES5
  - HES6
  - HES7
  - KRAS
  - HRAS
  - NRAS
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - LPA
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - STING1
  - MST1
  - STK4
  - STK3
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - RPSA
  - LRP1
  - PTPRA
  - MVP
  - LATS1
  - CHKA
  - AXIN1
  - AXIN2
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - RPS6KB1
  - RPS6KB2
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - YAP1
  - TAFAZZIN
  - WWTR1
  - CAT
  - CRAT
  - GLYAT
  - GATD3
  - HEY1
  - CCND1
  - SMAD1
  - SMAD4
  - SMAD5
  - SMAD6
  - SMAD7
  - SMAD9
  - SMAD2
  - SMAD3
  - HHIP
  - CCN2
  - CCN1
  - CCNE1
  - IGF2BP1
  - Cyclopamine
  - LY294002
  - saridegib
  - ACY-1215
  - Itraconazole
  - Cancer
---
